US Patent 9173929 Mucinous glycoprotein (MUC-1) vaccine
Patent 9173929 was granted and assigned to Oncothyreon on November, 2015 by the United States Patent and Trademark Office.
All edits
Edits on 3 Dec, 2023
Golden AI
Edits made to:
Article (+299 characters)
Article
Patent abstract
The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1 based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 09173929 Mucinous glycoprotein (MUC-1) vaccine US Patent 9173929 Mucinous glycoprotein (MUC-1) vaccine
Infobox
Patent Number
091739290
Patent Number
91739290
Edits on 31 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
091739290
Date of Patent
November 3, 2015
0Patent Application Number
105949920
Date Filed
April 1, 2005
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Jan, 2022
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 09173929 Mucinous glycoprotein (MUC-1) vaccine
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
09173929
Date of patent
November 3, 2015
Patent application number
10594992
Date Filed
April 1, 2005
Patent primary examiner
Find more entities like US Patent 9173929 Mucinous glycoprotein (MUC-1) vaccine
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.